• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不同放化疗方式及化疗方案对局部晚期非小细胞肺癌患者淋巴细胞减少症的影响。

The impact of different modalities of chemoradiation therapy and chemotherapy regimens on lymphopenia in patients with locally advanced non-small cell lung cancer.

作者信息

Li Yaqi, Fan Xingwen, Pei Yulei, Yu Qi, Lu Renquan, Jiang Guoliang, Wu Kailiang

机构信息

Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, China.

Shanghai Key Laboratory of Radiation Oncology, Shanghai, China.

出版信息

Transl Lung Cancer Res. 2024 Jun 30;13(6):1190-1200. doi: 10.21037/tlcr-24-60. Epub 2024 Jun 27.

DOI:10.21037/tlcr-24-60
PMID:38973960
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11225056/
Abstract

BACKGROUND

Chemotherapy and radiotherapy (RT) would induce lymphopenia, leading to a poor prognosis. This study investigated whether chemotherapy increased lymphopenia during RT and explored the impacts of different chemotherapy regimens on the lymphocyte counts of patients receiving RT.

METHODS

Clinical parameters and lymphocyte data were collected from 215 patients with locally advanced non-small cell lung cancer (LA-NSCLC). Severe lymphopenia (SRL) was defined as an absolute lymphocyte count (ALC) of ≤0.2×10 cells/μL. Patient overall survival (OS) was analyzed using the Kaplan-Meier method. The predictors of SRL were extracted using univariate and multivariate regression analyses with backward likelihood ratio elimination.

RESULTS

Compared with patients without SRL, patients with SRL with LA-NSCLC showed a poorer prognosis in terms of OS (P=0.003). Of the 215 patients, 130 underwent concurrent chemoradiotherapy (CCRT) and 85 underwent sequential chemoradiotherapy (SCRT). The OS was better in patients without SRL (in the CCRT group, P=0.01 and in the SCRT group, P=0.08). The mean ALCs for CCRT and SCRT did not differ significantly (P=0.27). The minimum ALC of CCRT was significantly lower than that of SCRT (P<0.0001). CCRT was a predictor of SRL (P=0.008). However, multivariate analysis showed that the different chemotherapy regimens were not predictors of SRL (all P>0.1).

CONCLUSIONS

In LA-NSCLC, the outcomes of patients with SRL were poorer than those without SRL. RT and chemotherapy were the main factors affecting SRL development, while different chemotherapy regimens were not significantly associated with lymphocyte counts in LA-NSCLC.

摘要

背景

化疗和放疗会导致淋巴细胞减少,从而预后不良。本研究调查了化疗是否会在放疗期间加重淋巴细胞减少,并探讨了不同化疗方案对接受放疗患者淋巴细胞计数的影响。

方法

收集了215例局部晚期非小细胞肺癌(LA-NSCLC)患者的临床参数和淋巴细胞数据。严重淋巴细胞减少(SRL)定义为绝对淋巴细胞计数(ALC)≤0.2×10⁹细胞/μL。采用Kaplan-Meier法分析患者总生存期(OS)。使用单因素和多因素回归分析及向后似然比消除法提取SRL的预测因素。

结果

与无SRL的LA-NSCLC患者相比,有SRL的患者在OS方面预后较差(P = 0.003)。215例患者中,130例接受同步放化疗(CCRT),85例接受序贯放化疗(SCRT)。无SRL的患者OS较好(CCRT组中,P = 0.01;SCRT组中,P = 0.08)。CCRT和SCRT的平均ALC无显著差异(P = 0.27)。CCRT的最低ALC显著低于SCRT(P < 0.0001)。CCRT是SRL的一个预测因素(P = 0.008)。然而,多因素分析表明,不同的化疗方案不是SRL的预测因素(所有P > 0.1)。

结论

在LA-NSCLC中,有SRL的患者预后比无SRL的患者差。放疗和化疗是影响SRL发生的主要因素,而不同的化疗方案与LA-NSCLC患者的淋巴细胞计数无显著相关性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1fa/11225056/db7bbfd657d0/tlcr-13-06-1190-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1fa/11225056/42bbb2effa24/tlcr-13-06-1190-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1fa/11225056/9dbbf7759d35/tlcr-13-06-1190-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1fa/11225056/9ee65966e405/tlcr-13-06-1190-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1fa/11225056/db7bbfd657d0/tlcr-13-06-1190-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1fa/11225056/42bbb2effa24/tlcr-13-06-1190-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1fa/11225056/9dbbf7759d35/tlcr-13-06-1190-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1fa/11225056/9ee65966e405/tlcr-13-06-1190-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1fa/11225056/db7bbfd657d0/tlcr-13-06-1190-f4.jpg

相似文献

1
The impact of different modalities of chemoradiation therapy and chemotherapy regimens on lymphopenia in patients with locally advanced non-small cell lung cancer.不同放化疗方式及化疗方案对局部晚期非小细胞肺癌患者淋巴细胞减少症的影响。
Transl Lung Cancer Res. 2024 Jun 30;13(6):1190-1200. doi: 10.21037/tlcr-24-60. Epub 2024 Jun 27.
2
Proton and Carbon Ion Radiation Therapy Decreased Severe Lymphopenia by Reducing Thoracic Vertebra and Aortic Doses in Non-Small Cell Lung Cancer Versus Intensity Modulated Radiation Therapy.质子和碳离子放射治疗通过降低非小细胞肺癌的胸椎和主动脉剂量,减少严重的淋巴细胞减少症,与强度调制放射治疗相比。
Int J Radiat Oncol Biol Phys. 2023 Jul 1;116(3):579-589. doi: 10.1016/j.ijrobp.2022.12.030. Epub 2022 Dec 28.
3
Proton beam therapy reduces the risk of severe radiation-induced lymphopenia during chemoradiotherapy for locally advanced non-small cell lung cancer: A comparative analysis of proton versus photon therapy.质子束疗法降低局部晚期非小细胞肺癌放化疗中严重放射性淋巴细胞减少症的风险:质子与光子治疗的对比分析。
Radiother Oncol. 2021 Mar;156:166-173. doi: 10.1016/j.radonc.2020.12.019. Epub 2020 Dec 24.
4
Hypofractionated concurrent chemoradiotherapy related lymphopenia and its association with survival in locally advanced non-small cell lung cancer patients.大分割同步放化疗相关淋巴细胞减少及其与局部晚期非小细胞肺癌患者生存的关系
Front Oncol. 2022 Nov 18;12:979384. doi: 10.3389/fonc.2022.979384. eCollection 2022.
5
Sequential Versus Concurrent Chemoradiation Therapy by Surgical Margin Status in Resected Non-Small Cell Lung Cancer.手术切缘状态对非小细胞肺癌根治术后序贯与同步放化疗的影响。
J Natl Compr Canc Netw. 2018 May;16(5):508-516. doi: 10.6004/jnccn.2018.7007.
6
The effect of different treatment modalities on survival in elderly patients with locally advanced non-small cell lung cancer.不同治疗方式对老年局部晚期非小细胞肺癌患者生存的影响。
Pulmonology. 2021 Jan-Feb;27(1):26-34. doi: 10.1016/j.pulmoe.2019.11.007. Epub 2019 Dec 12.
7
Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center.不可切除的局部晚期非小细胞肺癌的根治性放疗或放化疗:对某三级癌症中心213例患者的病例资料、治疗方法及治疗结果分析
Indian J Cancer. 2018 Apr-Jun;55(2):125-133. doi: 10.4103/ijc.IJC_469_17.
8
[Outcome of Nonsurgical Treatment for Locally Advanced Thymic Tumors].[局部晚期胸腺瘤非手术治疗的结果]
Zhongguo Fei Ai Za Zhi. 2016 Jul 20;19(7):483-8. doi: 10.3779/j.issn.1009-3419.2016.07.11.
9
Outcome of nonsurgical treatment for locally advanced thymic tumors.局部晚期胸腺瘤非手术治疗的结果
J Thorac Dis. 2016 Apr;8(4):705-10. doi: 10.21037/jtd.2016.01.79.
10
Concurrent Versus Sequential Chemoradiation Therapy in Completely Resected Pathologic N2 Non-Small Cell Lung Cancer: Propensity-Matched Analysis of the National Cancer Data Base.完全切除的病理 N2 期非小细胞肺癌的同期与序贯放化疗:国家癌症数据库的倾向评分匹配分析。
Ann Surg Oncol. 2018 May;25(5):1245-1253. doi: 10.1245/s10434-018-6399-4. Epub 2018 Feb 26.

引用本文的文献

1
Impact of Chemotherapy on Circulating Lymphocyte Subsets in Lung Cancer Patients.化疗对肺癌患者循环淋巴细胞亚群的影响
Cancer Manag Res. 2024 Sep 10;16:1205-1213. doi: 10.2147/CMAR.S475967. eCollection 2024.

本文引用的文献

1
Association Between Lymphopenia and Survival Outcomes in Esophageal Carcinoma Patients Receiving Combined Immunotherapy and Chemoradiotherapy.接受免疫联合放化疗的食管癌患者淋巴细胞减少与生存结局的关系。
Oncologist. 2023 Aug 3;28(8):e606-e616. doi: 10.1093/oncolo/oyad094.
2
Effects of lymphopenia on survival in proton therapy with chemotherapy for non-small cell lung cancer.淋巴细胞减少症对化疗联合质子治疗非小细胞肺癌患者生存的影响。
J Radiat Res. 2023 Mar 23;64(2):438-447. doi: 10.1093/jrr/rrac084.
3
Proton and Carbon Ion Radiation Therapy Decreased Severe Lymphopenia by Reducing Thoracic Vertebra and Aortic Doses in Non-Small Cell Lung Cancer Versus Intensity Modulated Radiation Therapy.
质子和碳离子放射治疗通过降低非小细胞肺癌的胸椎和主动脉剂量,减少严重的淋巴细胞减少症,与强度调制放射治疗相比。
Int J Radiat Oncol Biol Phys. 2023 Jul 1;116(3):579-589. doi: 10.1016/j.ijrobp.2022.12.030. Epub 2022 Dec 28.
4
Severe Radiation-Induced Lymphopenia Affects the Outcomes of Esophageal Cancer: A Comprehensive Systematic Review and Meta-Analysis.严重辐射诱导淋巴细胞减少症影响食管癌的预后:一项全面的系统评价和荟萃分析。
Cancers (Basel). 2022 Jun 20;14(12):3024. doi: 10.3390/cancers14123024.
5
Benefit of Concurrent Versus Sequential Chemoradiotherapy in Elderly Patients With Stage III Non-Small Cell Lung Cancer.同步放化疗与序贯放化疗对老年Ⅲ期非小细胞肺癌患者的疗效比较
Clin Lung Cancer. 2022 Mar;23(2):116-121. doi: 10.1016/j.cllc.2021.12.004. Epub 2021 Dec 17.
6
Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy.在接受维持性免疫治疗的 III 期 NSCLC 患者中,放化疗期间和之后的淋巴细胞动力学与剂量和结果相关。
Radiother Oncol. 2022 Mar;168:1-7. doi: 10.1016/j.radonc.2022.01.007. Epub 2022 Jan 13.
7
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
8
On the interplay between dosiomics and genomics in radiation-induced lymphopenia of lung cancer patients.在肺癌患者放疗诱导性淋巴细胞减少症中,剂量组学与基因组学的相互作用。
Radiother Oncol. 2022 Feb;167:219-225. doi: 10.1016/j.radonc.2021.12.038. Epub 2021 Dec 31.
9
Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy.立体定向体部放疗治疗局限性胰腺癌时,椎体和脾脏照射与淋巴细胞减少相关。
Radiat Oncol. 2021 Dec 24;16(1):242. doi: 10.1186/s13014-021-01969-1.
10
Current status and application of proton therapy for esophageal cancer.质子治疗食管癌的现状与应用。
Radiother Oncol. 2021 Nov;164:27-36. doi: 10.1016/j.radonc.2021.09.004. Epub 2021 Sep 14.